alectinib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
alectinib
Apr 30, 2024, 07:31 |
Insight
Top 5 posts of the week by Cancer Network
Cancer Network shared on their X/Twitter page: "View our top 5 posts of the week:…
Apr 26, 2024, 10:07 |
Drugs
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…
Apr 23, 2024, 10:44 |
Blog
Ben Solomon: A timely discussion with Narjust Florez about the ALINA trial
Ben Solomon, Lung Cancer Medical Oncologist at Peter MacCallum Cancer Centre, shared a post by…
Apr 19, 2024, 15:52 |
Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Apr 15, 2024, 13:28 |
Insight
Antonio Passaro: Release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on LinkedIn: ''I am thrilled…
Apr 15, 2024, 01:09 |
Blog
Antonio Passaro: Our editorial on the groundbreaking ALINA trial
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on X/Twitter: "Just published in…
Apr 14, 2024, 22:26 |
Insight
Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared a post on LinkedIn:…
Apr 13, 2024, 09:40 |
Drugs
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X: "Hot off…
Apr 12, 2024, 11:46 |
Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Oct 23, 2023, 15:35 |
Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
1
2
All:
11
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube